CT PHARMA RESEARCH WE CAN NOT STOP THINKING ABOUT THE FUTURE
The pharmaceutical sector, which has an important place in the world economy in terms of commercial volume, is one of the rapidly developing sectors in Turkey in parallel with other countries.
With the Out-Source R&D studies it has provided, CT Pharma Research has managed to become one of the important players in this field of the Turkish pharmaceutical industry in a very short time. CT Pharma Research, which provides services in its 200 square meter laboratories equipped with modern technology in the Technology Development Zone of Tübitak Gebze Campus, has made a big difference in the sector with its information security and ethical service understanding.
It was founded in 2012 by Pharmaceutical Biotechnologist by Dr. Şerhan Şimşek and Chemical Engineer Semra Aktaş Şimşek, was established with 100% domestic capital and makes a great contribution to the country's economy with the services it provides. Apart from the R&D services it provides to many domestic and foreign companies, we talked to the group's CEO, Dr. Şerhan Şimşek, who stated that they will bring dermocosmetic and innovative herbal products to the sector with its sister company TFLL Pharma, which it launched in 2017, about the company, the projects they have realized and their future goals.
Can you tell us the founding story of your company?
After working with my wife, Semra Aktaş Şimşek, in various R&D positions in the pharmaceutical industry for over 20 years, we decided to establish CT Pharma Research in 2012. Our aim in establishing our company was to be an alternative to companies that do not have their own R&D and try to close this gap by obtaining this service or technical files from countries such as India, China and Europe. In 2013, we started laboratory activities in the smallest units in Tübitak Gebze Campus Technology Development Zone. In the same year, we moved to our laboratory of 100 square meters, and in 2015, 200 square meters, where we carry out our activities. With our formulation development, validation and quality assurance units, we provide turnkey R&D services to 16 domestic and foreign pharmaceutical companies, the number of projects we have completed has exceeded 140 in five years.
What are the characteristics that distinguish you as an institution from other institutions?
When we established our company, we determined two basic principles. We owe our success today to our uncompromising commitment to these principles. The first of these is that we respect information security and ethical values. Our customer, to whom we provide product development services, is our sponsor, and we undertake that we will not work with any other company after we start working on the molecule and/or dosage forms he thinks. In other words, our sponsor company knows that the know-how we have developed belongs only to it. Being loyal to these values in our industry, where competition is intense, creates a great sense of trust in our customers. In this way, in a short period of 5 years, CT Pharma Research has reached a very different place in the sector. Our second basic principle is to make our customers' pharmaceutical companies feel like CT Pharma Research is their own R&D department. In all projects that come to us, we offer the most economical, most accurate and precise solutions to all possible problems that our customers may encounter at all stages of generic drug research and development activities, from molecule selection to licensing processes. We meet all of the R&D activities that our customers need.
Mr. Şerhan; Can you tell us about your work with TÜBİTAK MARTEK Technopark?
Another client of CT Pharma Research is himself. With this approach, we develop projects especially in the field of biotechnology. We have two projects completed with TÜBİTAK TEYDEP. Our third project is in the approval phase. All of our projects are in the field of pharmaceutical biotechnology and as CT Pharma Research we have a team specialized in therapeutic synthetic peptides. For this reason, our projects were especially supported in the priority area. Our product for biotechnological topical application has reached the stage of obtaining a patent with examination. Since 2016, as CT Pharma Research, we have started a project with TÜBİTAK MARTEK Technopark and MEDICANA hospitals for personalized cancer treatments as well as our R&D studies. We develop special therapeutic products to support chemotherapy for cancer patients, and we perform tests related to these developed products in our laboratory. Soon, the licensing processes for these drugs will also begin.
WE THINK TO MAKE A DIFFERENCE IN THE INDUSTRY WITH OUR OWN PRODUCTS.
As CT Pharma Research, we have started the R&D and licensing processes of our own products, which we mentioned above. For this purpose, we established a new company as TFLL Pharma at the beginning of 2017. TFLL Pharma; It will have an organization that will carry out the sales, marketing, licensing and distribution of the products developed by CT Pharma Research. We have 4 new dermocosmetic products for infant, child and maternal health. It will meet with the consumer in the second quarter of 2017 with the brand PLANTO BABY, completely herbal. We will have created a serious difference when our products in the field of dermocosmetic come to the market. Because we have developed these products by selecting plants with therapeutic effects to be sold in pharmacies.
Mr. Şerhan, can you tell us about your goals as a company?
We can not stop thinking about the future. This thought has become a mission that shapes our activities in every field. Accordingly, our primary goal is to be one of the leading companies in this field with our R&D activities in the current account deficit consisting of R&D expenditures and imported drugs. As part of our project to expand abroad, we are negotiating to start our activities in the KAUST (King Abdullah University Science And Technology) region in Jeddah in Arabia and in Belgium and England in Europe. Our other goals are to accelerate our progress in the field of biotechnology and to develop dosage forms that are not available in Turkey. We can count as being. As a company, we do everything we can to produce for our country, to work for our country, to produce without being dependent on foreign sources, and we will continue to do so.
